ArticleNature protocols2010
Construction and testing of engineered zinc-finger proteins for sequence-specific modification of mtDNA.
Article in Nature protocols, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Mitochondrial DNA homeostasis: A novel therapeutic target for neurodegenerative diseases.Neural regeneration research · 2026Article
- Mitochondrial genome microhomology-mediated editing by donor DNA delivery into mitochondria in human cells.Molecular therapy. Nucleic acids · 2026Article
- Trends and prospects in mitochondrial genome editing.Experimental & molecular medicine · 2023Review
- A library of base editors for the precise ablation of all protein-coding genes in the mouse mitochondrial genome.Nature biomedical engineering · 2023Article
- Site-specific CRISPR-based mitochondrial DNA manipulation is limited by gRNA import.Scientific reports · 2022Article
- The potential of mitochondrial genome engineering.Nature reviews. Genetics · 2022Review
- In vivo mitochondrial base editing via adeno-associated viral delivery to mouse post-mitotic tissue.Nature communications · 2022Article
- Engineering Genetic Systems for Treating Mitochondrial Diseases.Pharmaceutics · 2021Review
- The NIH Somatic Cell Genome Editing program.Nature · 2021Review
- TRMT2B is responsible for both tRNA and rRNA mRNA biology · 2020Article
- Manipulating and elucidating mitochondrial gene expression with engineered proteins.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2020Review
- METTL15 introduces N4-methylcytidine into human mitochondrial 12S rRNA and is required for mitoribosome biogenesis.Nucleic acids research · 2019Article
- NSUN2 introduces 5-methylcytosines in mammalian mitochondrial tRNAs.Nucleic acids research · 2019Article
- Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo.Nature medicine · 2018Article
- Pathogenic variants in glutamyl-tRNANature communications · 2018Article
- Biallelic C1QBP Mutations Cause Severe Neonatal-, Childhood-, or Later-Onset Cardiomyopathy Associated with Combined Respiratory-Chain Deficiencies.American journal of human genetics · 2017Article
- Article
- Human mitochondrial nucleases.The FEBS journal · 2017Review
- Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mtZFNs.Nucleic acids research · 2016Article
- Deficient methylation and formylation of mt-tRNA(Met) wobble cytosine in a patient carrying mutations in NSUN3.Nature communications · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Engineered zinc-finger proteins (ZFPs) are hybrid proteins developed to direct various effector domains (EDs) of choice to predetermined DNA sequences. They are used to alter gene expression and to modify DNA in a sequence-specific manner in vivo and in vitro. Until now, ZFPs have mostly been used to target DNA sites in nuclear genomes. This protocol describes how to adapt engineered ZFP technology to specifically modify the mammalian mitochondrial genome. The first step describes how to construct mitochondrially targeted ZFPs (mtZFPs) so that they are efficiently imported into mammalian mitochondria. In the second step, methods to test the basic properties of mtZFPs in vitro are described. Finally, we outline how the mtZFPs can be transiently transfected into mammalian cells and their mitochondrial import tested by both immunofluorescence and biochemical methods. The protocol can be completed within a week, although time-consuming DNA cloning steps may extend this.
Indexed as
Identifiers
20134433What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.